The US Food and Drug Administration has issued draft new guidance it will give to industry on the labeling of biosimilar products.
This has been published to give the chance for all interested parties – companies, health care providers and patients - to have their say on what is a highly important issue, as labeling communicates a product’s safety and effectiveness to the practitioners who decide whether it is appropriate for patients.
The new guidelines are aimed at ensuring that “new, safe and effective health care options become available for patients”, according to Leah Christl, associate director for therapeutic biologics in the Office of New Drugs in the FDA's Center for Drug Evaluation and Research.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze